Is This New Treatment Better Than It Used to Be?

Every single patient is different. And when you are randomizing this patience, by chance, you may have a group that has some tipe of a feature that is targeted by your medication,. That is basical not going to help that group. So its flawed at its essence. We think that we're very smart with these target agents and the epidema gos factor receptors inhibitors. But we started using egiopin inhibitors before we knew what theyere doing. All the cancer patients, yeu're getting an igio far inhibitors. And of course, ten % of them, they had some response. Nobody knew why. While they had a responsicos. Ten percent, they